Video - Results from #30

ASCO GU 2022 VL

Molecular Biomarkers in Upper-Tract Urothelial Carcinoma - Janet Kukreja Details Janet Kukreja joins Sam Chang to further highlight her presentation at GU ASCO 2022 focusing on clinical implications of molecular biomarkers in upper tract urothelial carcinoma (UTUC). Currently, the ideal marker does not exist, but we are on our way to more personalized medicine. Drs Chang and Kukreja highlight improved characterization, better identification, risk stratification, and then indiv...
The Future of Adjuvant and Neoadjuvant Therapy for Patients with Muscle-Invasive Bladder Cancer - Tracy Rose Details In this conversation with Sam Chang, Tracy Rose shares highlights from her GU ASCO 2022 presentation on novel therapies in bladder cancer and their toxicities, discussing the future of adjuvant and neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC). Biographies: Tracy L. Rose, MD, Assistant Professor of Medicine, Division of Oncology, The University of North Carolina at Ch...
Penile Squamous Cell Carcinoma Somatic Alterations - W. Michael Korn Details Charles Ryan is joined by Michael Korn, the Chief Medical Officer of Caris Life Sciences, to discuss the study results assessing the comprehensive genomic profiling of penile squamous cell carcinoma (SCC) and the impact of HPV status on immune-checkpoint inhibition-related biomarkers. Using the Caris Life Sciences dataset, this study aimed to report the landscape of somatic alterations and ICI-rel...
TALAPRO-3 Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Neeraj Agarwal Details Neeraj Agarwal joins Alicia Morgans for a conversation on the TALAPRO-3 data presented at the GU ASCO 2022 meeting. The TALAPRO-3 trial is a phase 3 trial assessing enzalutamide plus talazoparib (TALA) versus placebo plus enzalutamide (ENZA) in men with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC) and compares the combination of TALA plus ENZA versus placebo plus ENZA i...
The Effect of Durvalumab and Olaparib on Prolong Progression-Free Survival As First-Line Therapy in Platinum-Ineligible Patients With Unresectable Urothelial Carcinoma - The BAYOU Study – Jonathan Ros... Details Jonathan Rosenberg joins Alicia Morgans to discuss the results of the BAYOU trial. BAYOU is a randomized phase II study examining durvalumab and olaparib as first-line therapy in platinum-ineligible patients with unresectable stage IV urothelial carcinoma. Biographies: Jonathan E. Rosenberg, MD, Chief of the Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology; and the Enno W....
Treatment and Survival Differences in Patients With Urothelial Vs. Nonurothelial Bladder & Upper Tract Carcinomas - Jeanny Aragon-Ching Details Sam Chang and Jeanny Aragon-Ching discuss treatment and survival differences in patients with urothelial versus non-urothelial bladder and upper tract carcinomas an analysis from the National Cancer Database (NCDB). There is an increased need for learning more about urothelial and non-urothelial cancers because non-urothelial cancers typically have been known to have a worse prognosis than urothel...
The Next Wave of Novel Radiopharmaceuticals - Shahneen Sandhu Details Alicia Morgans is joined by Shahneen Sandhu to discuss her presentation at GU ASCO 2022 on targeting prostate-specific membrane antigen (PSMA), specifically lutetium, and the next wave of novel radiopharmaceuticals. Dr. Sandhu's presentation focused on where we go with PSMA treatments in the future. Biographies: Shahneen Sandhu, MD, Ph.D., MBBS, FRACP, Associate Professor, Consultant Medical Oncol...
Overall Survival With Stratification by Disease Volume and Metastatic Status – Analyses of the ARCHES Trial - Arun Azad Details Alicia Morgans and Arun Azad discuss a post hoc analysis of the ARCHES trial data presented at GU ASCO 2022 of overall survival by disease volume and progression to M1 HSPC after initial diagnosis with localized disease or presentation of de novo mHSPC at initial diagnosis. Biographies: Arun Azad, MBBS, PhD, FRACP, Medical Oncologist, Associate Professor, Department of Medicine, Peter MacCallum Ca...
Advanced Prostate Cancer Practice Informing Data Presented at ASCO GU 2022 - Oliver Sartor Details Oliver Sartor joins Alicia Morgans to reflect on prostate cancer data presented during ASCO GU, highlighting data from three studies. Dr. Sartor discusses the phase 3 ARASENS trial, the phase 3 MAGNITUDE study, and the phase 3 PROpel trial. They discuss their perspectives on how these data will inform practice in the future. Biographies: A. Oliver Sartor, MD, Professor of Medicine and Medical Dire...
Real-World Understanding of the Prevalence of Potentially Targetable DNA Damage Repair Alterations – The PROMISE Registry – Heather Cheng Details Heather Cheng joins Alicia Morgans to discuss the trial in progress poster presented at GU ASCO 2022 on the PROMISE Registry. The goal of the PROMISE registry is to offer genetic testing for men with prostate cancer regardless of the stage of their disease. The registry will recruit over five years, with fifteen years of planned follow-up. Biographies: Heather H. Cheng, MD, PhD, Director, Seattle...

ASCO GU 2022 VL

Login